







an Open Access Journal by MDPI

The Microbiome-Immunity-Cancer Axis in Cancers

Guest Editors:

Dr. Anguan Shang

Dr. William Cho

Dr. Zongxin Ling

Deadline for manuscript submissions:

closed (31 May 2023)

Message from the Guest Editors

Recently, it came to light that the microbiota is a critical regulator of pro-tumorigenic inflammation that has long been suspected to play a significant role in cancer development. On one hand, pathogenic bacteria can contribute to cancer progression via inducing a variety of tumor-promoting inflammatory responses and initiating a pro-tumorigenic microenvironment. On the other hand. beneficial commensals prevent inflammation stimulate the host anti-cancer immunity. Thus, a delicate balance between the microbiomes and the immune system plays a critical role in the development or prevention of cancer.

The scope of this topic is to contribute to the understanding of the mechanisms that govern how oncomicrobes influence the microbiota and shape the immune system to affect anti-tumor immunity, cancer immunosurveillance, and response to immunotherapies. Advances in all those fields greatly enable the discovery of novel biomarkers for diagnosis and prognosis, as well as expedite the design of novel microbiome-manipulating strategies to prevent, abort, and treat cancers.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us